EXEL
Exelixis, Inc.
Biotechnology · Healthcare · United States
50.61
close · 2026-08-13
value
63
cheaper than peers63
quality
89
stronger fundamentals89
ranked against
Biotechnology (commercial)
value
quality
101 peerswide variation
Value inputs
| measure | company | vs peers |
| price to sales | 5.52× | 75 |
| forward P/E | 12.44× | 71 |
| EV to EBITDA | 13.66× | 59 |
| price to book | 6.83× | 38 |
4 of 12 measures available
Quality inputs
| measure | company | vs peers |
| operating margin | 41.1% | 93 |
| return on equity | 41.0% | 89 |
| debt to equity | 8.8% | 67 |
| revenue growth | 10.0% | 33 |
4 of 4 measures available
Facts
| market cap | $13B |
| free cash flow | $629.1M |
| employees | 1,077 |
| first trade | 2000-04-17 |
| next earnings | 2026-08-05 |
| fundamentals updated | 2026-08-06 |